Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188111 | 1.00 | MCHR1 (0.48) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL188535 | 1.00 | MCHR1 (0.48) | MCHR1MAP4K4KDM4EGAAMAPT | |
| Hydrochloric Acid SCHEMBL5388918 | 0.98 | MCHR1 (0.47) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL3440096 | 0.90 | MAPT (0.49) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL1409679 | 0.89 | MAPT (0.53) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL6223422 | 0.89 | MAPT (0.51) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL4794629 | 0.86 | MAPT (0.56) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL189433 | 0.85 | MAPT (0.47) | MCHR1MAP4K4KDM4EGAAMAPT | |
| SCHEMBL14924424 | 0.84 | MCHR1 (0.49) | MCHR1MAP4K4RORCKCNH2 | |
| SCHEMBL34469712 | 0.84 | MCHR1 (0.49) | MCHR1MAP4K4RORCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8507505-B2 | Dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-1986646-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007093364-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093363-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | MCHR1 1838/4885MAP4K4 1267/4885KDM4E 2966/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MCHR1 4629/4885MAP4K4 103/4885KDM4E 1234/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MCHR1 4629/4885MAP4K4 103/4885KDM4E 1234/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | MCHR1 2068/4885MAP4K4 1224/4885KDM4E 2896/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MCHR1 4629/4885MAP4K4 103/4885KDM4E 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.